• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

INSMED, INC.

NASDAQ:INSM

$2.98 -$0.02 (-0.67%)

Quote as of

Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE In Patients With Non-tuberculous Mycobacterial Lung Disease

Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease

Insmed appoints Donald Hayden as executive chairman of the board

Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman

Insmed Inc. (INSM) Broke Out To Nearly A 2-Month High On FDA News

Insmed reports Q1 EPS (28c), one estimate (38c)

Tyson, Disney, Insmed are market movers

Tyson, Disney, Insmed are market movers

Insmed stock soars after FDA ends hold on key lung drug

Insmed rises 63.7%

Insmed rises 53.7%

Pre-market Movers For May 7 (AIG, CTSH, TSN, INSM, VRTX, GTSI, BSFT)

Insmed rises 48.9%

Insmed (INSM) Says Clinical Hold on ARIKACE in CF Patients Lifted

Insmed shares halted, news pending

Insmed to Host 2012 First Quarter Earnings Conference Call

Insmed doses first patient in European study of Arikace

Insmed Announces First Patient Dosed In Pivotal European Phase 3 Clinical Study Of ARIKACE® In Cystic Fibrosis Patients With Pseudomonas Lung Infections

Insmed Announces First Patient Dosed in Pivotal European Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections

Insmed, Inc. (INSM) Reports Q4 Earnings of $0.30

Insmed Announces Fourth Quarter and Full-Year 2011 Financial Results

Insmed reports Q4 EPS (33c), consensus (38c)

Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call

Insmed Incorporated Provides Update On Clinical Program For ARIKACE®

Insmed provides update on clinical program for ARIKACE

Insmed (INSM) Commences ARIKACE Phase 2 in NTM Lung Disease Patients, Phase 3 in CF Patients w/ Pa

Insmed Incorporated Provides Update on Clinical Program for ARIKACE®

Insmed Incorporated Provides Corporate Update

Insmed Inc. (INSM) Surged To Over A 3-Month High On FDA News

Insmed Incorporated Provides Corporate Update.

24/7 Wall St. Closing Bell (GOOG, JCI, VLO, TSCO, HUM, INTC, IBM, BAC, AXP, GE, SLB, STI, INSM, TLB, SHLD, NCIT, CCOI)

FDA Lifts Clnical Hold On Insmed's Lung Disease Drug Arikace; Stock Up - Update

Morning Movers (INSM, ASTI, CCOI, GOOG, ALTH)

Insmed, Google, Microsoft, NCI, Skyworks, SunTrust: U.S. Equity Movers

Pre-market Movers For Jan 20 (STI, MSFT, SLB, GE, GOOG, PH, FITB, SON, INSM)

FDA Lifts Clinical Hold on Insmed (INSM) ARIKACE in NTM Patients; Continues CF Negotiations

Insmed Incorporated Provides Corporate Update

Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference

Insmed Inc. Reports Operating Results (10-Q)

Insmed: undertaking comprehensive evaluation of next steps for ARIKACE program

See More Articles...